NEW YORK (GenomeWeb) – OncoCyte said after the close of the market on Tuesday that its 2018 Q1 net loss shrank 19 percent year over year, as it moves forward with studies intended to support a final clinical validation by the end of the year.

The liquid biopsy firm's net loss for the three months ended March 31, 2018 was $3.8 million, or $.12 per share, compared to a net loss of $4.7 million, or $.16 per share, in the same quarter last year. It matched the consensus Wall Street estimate of a loss of $.12 per share.

To read the full story....

Register for Free.

...and receive Daily News bulletins.

Already have an account?
Login Now.

York University researchers find genomic evidence of inbreeding in the yellow-banded bumblebee, according to Reuters.

In its survey of US adults, the Pew Research Center finds that views on the genetic engineering of animals depend on why it's done.

The Scientist reports agricultural researchers are working on a gene-stacking tool.

In Nature this week: statistical method for overcoming case-control imbalance issues, and more.